IRIS
PIERONI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.159
AS - Asia 2.970
EU - Europa 1.784
SA - Sud America 446
AF - Africa 179
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.548
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.090
SG - Singapore 1.009
CN - Cina 769
VN - Vietnam 518
IT - Italia 374
BR - Brasile 343
IE - Irlanda 299
SE - Svezia 232
HK - Hong Kong 226
DE - Germania 171
FI - Finlandia 152
TR - Turchia 114
ZA - Sudafrica 107
FR - Francia 104
NL - Olanda 97
GB - Regno Unito 66
RU - Federazione Russa 65
IN - India 62
AT - Austria 51
AR - Argentina 40
KR - Corea 40
CA - Canada 29
CI - Costa d'Avorio 28
IQ - Iraq 28
ES - Italia 27
ID - Indonesia 27
JP - Giappone 26
MX - Messico 26
PL - Polonia 25
BE - Belgio 24
PK - Pakistan 22
BD - Bangladesh 21
PH - Filippine 20
CZ - Repubblica Ceca 19
UA - Ucraina 15
SA - Arabia Saudita 14
VE - Venezuela 14
CO - Colombia 13
LT - Lituania 12
LU - Lussemburgo 12
EC - Ecuador 11
GH - Ghana 11
UZ - Uzbekistan 11
MA - Marocco 9
AE - Emirati Arabi Uniti 7
CL - Cile 7
EG - Egitto 7
TH - Thailandia 7
TW - Taiwan 7
BO - Bolivia 6
IL - Israele 6
MY - Malesia 6
PY - Paraguay 6
AL - Albania 5
AU - Australia 5
AZ - Azerbaigian 5
KZ - Kazakistan 5
TN - Tunisia 5
CH - Svizzera 4
DZ - Algeria 4
KG - Kirghizistan 4
LV - Lettonia 4
PA - Panama 4
PE - Perù 4
SN - Senegal 4
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
CR - Costa Rica 2
CY - Cipro 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RS - Serbia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
EE - Estonia 1
GE - Georgia 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
ME - Montenegro 1
ML - Mali 1
Totale 8.539
Salva come PNG Salva come JPEG
Città #
Singapore 552
Ashburn 464
Chandler 339
Dublin 296
San Jose 262
Dallas 255
Hong Kong 209
Santa Clara 206
Beijing 163
Ho Chi Minh City 158
Ann Arbor 146
Hanoi 118
Parma 112
Johannesburg 99
Boardman 91
Los Angeles 77
Izmir 73
Shanghai 73
Dearborn 72
Munich 63
Lauterbourg 62
Nanjing 62
Hefei 59
Princeton 57
Helsinki 55
New York 47
Columbus 46
Wilmington 43
Bremen 40
Vienna 37
Chicago 35
São Paulo 33
Moscow 31
Turku 30
Council Bluffs 29
Abidjan 28
The Dalles 28
Bologna 24
Buffalo 24
Guangzhou 24
Seoul 23
Haiphong 22
Frankfurt am Main 21
Kocaeli 21
Warsaw 21
Da Nang 20
London 20
Atlanta 19
Jakarta 19
San Mateo 18
Seattle 18
Shenyang 18
Tokyo 18
Brooklyn 17
Milan 17
Nanchang 17
Brussels 16
Falls Church 16
Hebei 16
Houston 15
Changsha 14
Chennai 14
Brasília 13
Jinan 13
Brno 12
Jiaxing 12
Norwalk 12
Orem 11
Amsterdam 10
Baghdad 10
Curitiba 10
Kyiv 10
Nuremberg 10
Accra 9
Istanbul 9
Des Moines 8
Fremont 8
Luxembourg 8
Montreal 8
Porto Alegre 8
Rio de Janeiro 8
Rome 8
Bengaluru 7
Cairo 7
Caracas 7
Denver 7
Florence 7
Manchester 7
Phoenix 7
Stockholm 7
Tashkent 7
Tianjin 7
Verona 7
Belo Horizonte 6
Can Tho 6
Dalmine 6
Hải Dương 6
Modena 6
Mumbai 6
Ninh Bình 6
Totale 5.338
Salva come PNG Salva come JPEG
Nome #
Discovery of Substituted (2-Aminooxazol-4-yl)Isoxazole-3-carboxylic Acids as Inhibitors of Bacterial Serine Acetyltransferase in the Quest for Novel Potential Antibacterial Adjuvants 263
Investigational Studies on a Hit Compound Cyclopropane-Carboxylic Acid Derivative Targeting O-Acetylserine Sulfhydrylase as a Colistin Adjuvant 214
Refining the structure−activity relationships of 2-phenylcyclopropane carboxylic acids as inhibitors of O-acetylserine sulfhydrylase isoforms 193
Nuovi composti antimicrobici 193
Exploring the chemical space around N-(5-nitrothiazol-2-yl)-1,2,3-thiadiazole-4-carboxamide, a hit compound with serine acetyltransferase (SAT) inhibitory properties 191
A competitive o‐acetylserine sulfhydrylase inhibitor modulates the formation of cysteine synthase complex 190
Inhibitors of O-Acetylserine Sulfhydrylase with a Cyclopropane-Carboxylic Acid Scaffold Are Effective Colistin Adjuvants in Gram Negative Bacteria 187
Integration of Enhanced Sampling Methods with Saturation Transfer Difference Experiments to Identify Protein Druggable Pockets 177
Aspergillus fumigatus tryptophan metabolic route differently affects host immunity 172
Rational Design, Synthesis and Preliminary Structure-Activity Relationships of α-Substituted-2-Phenylcyclopropane Carboxylic Acids as Inhibitors of Salmonella Typhimurium O-Acetylserine Sulfhydrylase 171
Inhibition of Nonessential Bacterial Targets: Discovery of a Novel Serine O-Acetyltransferase Inhibitor 171
Chemical Probes to Investigate Central Nervous System Disorders: Design, Synthesis and Mechanism of Action of a Potent Human Serine Racemase Inhibitor 170
Accepting the Invitation to Open Innovation in Malaria Drug Discovery: Synthesis, Biological Evaluation, and Investigation on the Structure-Activity Relationships of Benzo[b]thiophene-2-carboxamides as Antimalarial Agents 165
2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry 165
Preliminary structure−activity relationships analysis on N-(3,5-dichlorophenyl)-4,5-dihydronaphtho[1,2-d]thiazol-2-amine, a disruptor of mycobacterial energetics 162
Inhibitors of the sulfur assimilation pathway in bacterial pathogens as enhancers of antibiotic therapy 160
Discovering a new class of antifungal agents that selectively inhibits microbial carbonic anhydrases 160
Cyclopropane-1,2-dicarboxylic acids as new tools for the biophysical investigation of O-acetylserine sulfhydrylases by fluorimetric methods and saturation transfer difference (STD) NMR 159
Antituberculosis agents: Beyond medicinal chemistry rules 157
Cycloserine enantiomers are reversible inhibitors of human alanine:glyoxylate aminotransferase: Implications for Primary Hyperoxaluria type 1 156
Towards the sustainable discovery and development of new antibiotics 150
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections 146
Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery 143
Modulation of bacterial metabolism by the microenvironment controls MAIT cell stimulation 141
Cyclopropane derivatives as potential human serine racemase inhibitors: unveiling novel insights into a difficult target 140
Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit–to–lead optimization and release of a novel antitubercular chemotype via scaffold derivatization 139
Blocking cysteine biosynthesis in Salmonella typhimurium: the moonlighting enzyme CysK as a potential antibiotic target 139
Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics 139
Discovery of novel fragments inhibiting O-acetylserine sulphhydrylase by combining scaffold hopping and ligand–based drug design 139
A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin 137
Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A 137
Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design 131
Crystal structure of Aspergillus fumigatus AroH, an aromatic amino acid aminotransferase 129
Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1 128
In vitro digestion of zingiber officinale extract and evaluation of stability as a first step to determine its bioaccesibility 128
Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches 121
Challenging the drug-likeness dogma for new drug discovery in Tuberculosis 121
Quorum sensing inhibitors (QSIs): a patent review (2019–2023) 119
Sodium Hyaluronate Microparticles for Pulmonary Delivery of Anti-mycobacterial Drugs 119
Derivatives of 3-isoxazolecarboxylic acid esters - a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis 118
Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases 118
Design, Synthesis and Investigation onthe Structure–Activity Relationships of N-Substituted 2-Aminothiazole Derivatives as Antitubercular Agents 117
An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria 117
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy 114
Biochemical characterization of Aspergillus fumigatus AroH, a putative aromatic amino acid aminotransferase 114
Modulation of bacterial metabolism by the microenvironment controls MAIT cell stimulation article 111
6-Hydrogen-8-Methylquinolones Active Against Replicating and Non-replicating Mycobacterium tuberculosis 110
Pheochromocytoma-induced cardiogenic shock: A multicentre analysis of clinical profiles, management and outcomes 102
Preliminary structure - Activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains 94
From 6-aminoquinolone antibacterials to 6-amino-7- thiopyranopyridinylquinolone ethyl esters as inhibitors of staphylococcus aureus multidrug efflux pumps 93
Structural analogs of huperzine A improve survival in guinea pigs exposed to soman 92
Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds: a patent evaluation of US2019343869(A1) 91
Synthesis of 7-desmethyl analogs of (+)- and (-)-huperzine A 83
NOC chemistry for tuberculosis - Further investigations on the structure-activity relationships of antitubercular isoxazole-3-carboxylic acid ester derivatives 83
Indoleamides are active against drug-resistant mycobacterium tuberculosis 82
Searching for innovative quinolone-like scaffolds: Synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives 77
Synthesis and Structure-Activity Relationships of Lansine Analogues as Antileishmanial Agents 75
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway 75
Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains 70
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters 70
Pyrido[1,2-a]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB 69
Spectinamides: A challenge, a proof, and a suggestion 69
In pursuit of natural product leads: Synthesis and biological evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4- carboxylic acid (A-33853) and its analogues: Discovery of N-(2-benzoxazol-2- ylphenyl)benzamides as novel antileishmanial chemotypes 69
Synthesis, biological evaluation, and structure-activity relationships of N -benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), trypanosomes, and leishmania 68
Benzotriazole derivatives as alternate O-acetylserine sulfhydrylase substrates to impair cysteine biosynthesis in Gram-negative bacteria 66
Mutation of Rv2887, a marR-Like gene, confers mycobacterium tuberculosis resistance to an imidazopyridine-based agent 64
Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes 60
Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. A potent and selective series for further drug development 59
Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype 57
Totale 8.709
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.099
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.099
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 0 0 0 0 41 17 21
2021/2022379 15 28 25 25 10 38 20 26 35 22 21 114
2022/20231.261 118 138 79 100 146 149 7 65 374 15 41 29
2023/2024507 24 40 17 28 49 72 48 44 26 28 40 91
2024/20251.751 64 90 144 95 151 221 109 69 155 163 195 295
2025/20263.799 414 357 554 359 563 225 448 157 470 252 0 0
Totale 8.709